The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | Future directions for CAR T-cell therapy in MCL
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, explains that Bruton’s tyrosine kinase (BTK) inhibitors continue to be the first-choice treatment, but CAR T-cell therapy has gained prominence in mantle cell lymphoma (MCL) since the approval of brexucabtagene autoleucel for second line. In high-response patients, CAR T-cells could be considered in earlier lines, given that the performance CAR T-cells was similar in groups with both high and less-high response features, like blastoid MCL or TP53 mutations. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech
